The role of thalidomide in dermatology
- PMID: 34779533
- DOI: 10.1111/ced.15019
The role of thalidomide in dermatology
Abstract
Thalidomide is a medication that has been in existence for over half a century, and has proven to be useful and effective in severe dermatological conditions. For dermatologists, the ability of thalidomide to reduce the levels of the cytokine tumour necrosis factor-α, along with its immunomodulatory and anti-angiogenic properties, is of great significance, with the added advantage of being an oral medication. Its use is of course strictly monitored, owing to its potential adverse effects (AEs), particularly teratogenicity, with precautions taken to ensure its safe and correct use by both prescriber and patient. In this review, we look at the background and mechanism of action of thalidomide, provide an overview of conditions it can be used for with case examples, explain the potential AEs and monitoring requirements, and discuss future developments.
© 2021 British Association of Dermatologists.
Comment in
-
Thalidomide for necrobiotic xanthogranuloma.Clin Exp Dermatol. 2022 Apr;47(4):769-770. doi: 10.1111/ced.15047. Epub 2021 Dec 29. Clin Exp Dermatol. 2022. PMID: 34856016 No abstract available.
-
Comment on: 'The role of thalidomide in dermatology'.Clin Exp Dermatol. 2022 May;47(5):982-983. doi: 10.1111/ced.15096. Epub 2022 Feb 2. Clin Exp Dermatol. 2022. PMID: 34997621 No abstract available.
References
-
- Vargesson N. Thalidomide-induced teratogenesis: history and mechanisms. Birth Defects Res C Embryo Today 2015; 105: 140-56.
-
- Faver IR, Guerra SG, Su WPD, El-Azhary R. Thalidomide for dermatology: a review of clinical uses and adverse effects. Int J Dermatol 2005; 44: 61-7.
-
- Lenz W. Thalidomide and congenital abnormalities. In: Problems of Birth Defects, vol. 199. (Persaud TVN ed). Netherlands: Springer, 1962.
-
- McBride WG. Thalidomide and congenital abnormalities. Lancet 1961; ii: 90927-8.
-
- Sampaio EP, Sarno EN, Galilly R et al. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991; 173: 699-703.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources